12:00 AM
Jan 27, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MatriStem MicroMatrix: Phase IV started

ACell began a single-blind, U.S. Phase IV trial to compare standard of care (SOC) plus MatriStem MicroMatrix particles or MatriStem Wound Matrix sheets vs. SOC plus Dermagraft in...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >